WIXOM, Mich., Nov. 4, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported today third quarter 2009 sales of $14.2 million, up 4.6% from $13.5 million in the third quarter of 2008. Loss for the third quarter 2009 was ($1.5) million or ($.11) per share compared to ($2.5) million or ($.18) per share for the third quarter of 2008.
